Forward Looking Statement

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends" "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this presentation may include forward looking information relating to the Phase 3 BETonMACE2 clinical trial, Covid-19, vascular cognitive dementia, chronic kidney disease, Fabry disease and pulmonary arterial hypertension clinical trials, and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Donald McCaffrey
Email: don@resverlogix.com
Phone: 587-390-8887
Website: www.resverlogix.com
Resverlogix at a Glance

- Resverlogix Corp. is a Canadian public company developing an advanced cardiovascular drug called apabetalone. We are pioneering a technology that has the ability to turn multiple disease causing genes on or off. No actual change to the human DNA occurs. Our exciting breakthrough technology places Resverlogix as a world leader in utilizing “epigenetics” to regulate disease-causing genes.

- Apabetalone, was awarded **FDA Breakthrough Therapy Designation (BTD) in 2020.** This is the highest designation that a drug can receive from the FDA. BTD has only been awarded to 130 drugs previously and apabetalone is the first drug ever for mainstream cardiovascular development.

- Apabetalone’s advanced approach has been tested in over **4,200 man years of treatment** and has demonstrated its positive biological effects on patients with diseases such as:
  - Cardiovascular disease (CVD),
  - Diabetes mellitus (DM)
  - Chronic kidney disease (CKD).
  - Non-Alcoholic Fatty Liver disease (NAFLD)
  - Vascular Dementia
  - Pulmonary Arterial Hypertension
  - And very soon to be - COVID-19

<table>
<thead>
<tr>
<th>Stock Symbol</th>
<th>TSX: RVX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Cap</td>
<td>~$220MM&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Shares Outstanding</td>
<td>241MM&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

---

1. As at May 2021.
Health Canada Approves COVID-19 Trial

06 April 2021

Resverlogix Corp., Canada
e/o Sue Wehner
President
Med-Script Associates Ltd.
176 Chemin St-Henri
STE-MARTHE, Quebec
J0P 1W0

No Objection Letter RE: Protocol # RVX222-CS-023 (Version 1.1)

Dear Sue Wehner:

I am pleased to inform you that the information and material to support your Clinical Trial Application for RVX000222
(APABETALONE), control number 250480, received on March 23, 2021, have been reviewed and we have no objection to your
proposed study.

I would remind you of the necessity of complying with the Food and Drug Regulations, Division 5, in the sale of this product for
clinical testing. In addition, the regulations impose record keeping responsibilities on those conducting clinical trials. You are
also reminded that all clinical trials should be conducted in compliance with the Therapeutic Products Directorate’s Guideline for
Good Clinical Practice.

You are reminded of the following requirements:

As the result of very safe and promising data Health Canada has granted
Resverlogix approval to conduct a COVID-19 clinical
Significant Apabetalone Publications – COVID-19
Dual Mechanism Approach – ACE2 reduction and Cytokine Storm

New Results

Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro

Dean Gilham, Audrey L Smith, Li Fu, Dalia Y Moore, Abenaya Muralidharan, St. Patrick M Reid, Stephanie C Stotz, Jan O Johansson, Michael Sweeney, Norman CW Wong, Ewelina Kulikowski, Dalia El-Gamal

doi: https://doi.org/10.1101/2021.03.10.432949

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2

Number of US Deaths Due to Current Diseases in 2020
Posted on CNN - Dec. 2020 – AGM Slide

- **250k** Covid-19 deaths
- **670.6k** Heart disease
- **612.7k** Cancer
- **45.4k** Other causes
- **42.2k** Other causes
- **142k** Other causes

[Graph showing various disease-related deaths]
Number of US Deaths Due to Current Diseases in 2020
COVID-19 Updated to June 2021

- 600k COVID-19 deaths
- 670.6k Heart disease
- 612.7k Cancer
- 42.2k Other causes
- 45.4k Other causes
- 142k Other causes

Total: 1281.3k deaths
COVID-19 CLINICAL TRIAL LAUNCH - 2021
Resverlogix’ First Short Term Revenue Potential

**Trial Size**
100 patients

**Basic Trial Design**
- 4 week open label COVID-19 study for hospitalized patients
- Endpoints will be based on WHO and NIH guidelines
- Patients will have had symptoms for 7 days or less.

**Clinical Cost est.**
$3,000,000 USD
To be paid for by either RVX or by various Government interests under application

**Health Canada Trial Approval & Patient Enrollment**

**A larger Phase 3 trial will launch in the USA later this year**

**Phase 3 should be faster than vaccine trials as safety is already in place**

**Emergency supply, manufacturing & partnership agreements can commence during final P3 emergency trial**

**Long term potential is large as our dual mechanism approach should include related corona viruses and their variants**

**Reformulation to a tablet form**

**Fixed dose combo with an existing SGLT2**

**Time released once a day formulation**

**Pre-Clinical scale up of commercial supply**

**Chemistry preparation would be expedited under emergency management rules**

Desired chemistry upgrades, other than commercial scale up, NOT required for this program but can happen in parallel regardless.
End-to-end commercial strategy, operational excellence and a success share delivery model:

- Minimize financial exposure
- Keep revenues
- Maintain full ownership
Adding more strength for clients every day

- 570+ MDs, RNs, PharmDs
- 3,500~ Employees
- 25~ Locations
- 25 Patient Service Programs
- 150+ Brands
- 80+ Countries Served
- 100% of the Top 25 Bio-pharma Companies
- 500+ Life Science Clients
- 100+ Therapeutic Areas
- 500+ Employees

Bio-pharma: Adding more strength for clients every day
Lead Program Also Advancing
FDA Approves Breakthrough Therapy Designation

“A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.”

FDA Website

As the result of very safe and promising data the FDA granted Resverlogix the coveted **Breakthrough Therapy Designation**
**Efficacy - The Drug Works!** Trials confirmed a highly significant reduction in Death, Heart Attacks and CHF

- **Hazard Ratio = 0.37 (95% CI. 0.22 – 0.62)**
  - **p=0.0002**

- **Apabetalone** was well tolerated with similar rates of adverse events compared to placebo

- The effect of the co-administration of apabetalone and SGLT2 or DPP4 inhibitors – quantified by CV death, non-fatal MI, stroke and hospitalization for congestive heart failure (CHF) – illustrated a significant reduction of events compared to placebo and SGLT2 or DPP4 inhibitors
  - **HR = 0.37 (95% CI. 0.22–0.62; p=0.0002)**

---

**Apabetalone treatment led to a significant 63% hazard reduction of MACE and hospitalization for Congestive Heart Failure (CHF) compared to placebo in patients receiving SGLT2 or DPP4 Inhibitors**
Kaplan-Meier Estimates by CKD/Non-CKD for MACE Apabetalone Compared to Placebo

Source: Kalantar-Zadeh et al 2020; Apabetalone in CKD and MACE; publication pending

CKD Group (eGFR < 60)

- Placebo Events - 35/164 (21.3%)
- Apabetalone Events - 13/124 (10.5%)
- Hazard Ratio = 0.50 [95% CIs: 0.26, 0.96; \(p=0.03\)]

Apabetalone treatment led to a significant 50% hazard reduction of MACE compared to placebo in patients with CKD

Non-CKD Group (eGFR ≥ 60)

- Placebo + Top Standard of Care
- Apabetalone + Top Standard of Care

Source: Kalantar-Zadeh et al 2020; Apabetalone in CKD and MACE; publication pending
**TARGETED - GLOBAL DEVELOPMENT PLAN**

Planning details between Resverlogix and various potential partners

**Trial Size**
- 3,600 patients

**Basic Trial Design**
- Type 2 Diabetes patients post ACS 7-180 days
- Estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m²
- SGLT2 inhibitor if clinically indicated mandated for all subjects
- Endpoint, time to the first occurrence of narrowly defined MACE (CV death and MI) or hospital admission for CHF

**Clinical Cost est.**
- $60-70,000,000 USD
  - To be paid for by the Pharma side in a partnership agreement

**Timeline**
- 2021: Patient enrollment will start H2 2021. (pending COVID-19 issues)
- 2021: Fixed dose combo with an existing SGLT2
- 2022: Interim analysis of 300 targeted patient events should happen 6 months after enrollment
- 2022: Time released once a day formulation
- 2023: Pre-Clinical scale up of commercial supply
- 2023: Chemistry preparation could be done in 12 months.

**Pending interim success**
- FDA approval is possible due to the Breakthrough Therapy Designation

**Preferred chemistry upgrades can be done in parallel**
- Reformulation to a tablet form

**Chemistry preparation could be done in 12 months.**
Resverlogix 12 Month Key Milestones

**June**
- BETonMACE CKD subgroups results presented at ERA-EDTA
- FDA confirms key aspects of BETonMACE2 registration enabling study

**October**
- 12MM USD conversion of debenture; Entered into $10MM USD definitive stock purchase agreement
- Publication focused on apabetalone’s potential for COVID-19
- Filing of new IP for apabetalone in combination with oral anti-diabetic therapies

**November**
- Health Canada approved apabetalone for a COVID-19 trial
- Filing of new IP for apabetalone in combination with oral anti-diabetic therapies

**April**
- American Society of Nephrology published very positive kidney data regarding apabetalone
- Biomedicines Journal published positive UNMC data regarding apabetalone and COVID-19 in lung cells
- Resverlogix closes over $12MM CAD in financing including $6MM USD from Hepalink

**March**
- CELL Journal published Resverlogix COVID-19 data

**August**
- $2MM USD private placement

**June**
- Critical Eversana deal announced